TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03959085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo testicular radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo testicular radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo cranial radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo cranial radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo cranial radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo cranial radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02388906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo matching Ipilimumab
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo matching Nivolumab
Description: Specified dose on specified days
Study: NCT04410367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F fluciclovine
Description: 18F fluciclovine injection, 185 MegaBecquerel (MBq) (5 Millicurie (mCi)) ± 20%, delivered as an intravenous bolus
Study: NCT03764475

Intervention type: DRUG
Group type: OTHER
Intervention: Roflumilast
Description: Roflumilast cream 0.3% for topical application
Study: NCT04556552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive VN stimulation (nVNS)
Description: Stimulation of vagus nerve with active device. Participants will be administered nVNS using the electroCore GammaCore-S non-invasive VNS device. The intensity of the stimulus will be adjusted by the user, to the maximum tolerable level to ensure nVNS without causing excessive pain, the burst frequency to 5 kHz, and the envelope frequency to 25 Hz.~The duration of delivery will be 2 minutes, and the beginning will coincide with initiation of acquisition of the HR-PET scan which will be 90 seconds in duration; following an additional 8 minutes, a second VNS delivery will be administered, in conjunction with which another scan will be obtained.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen (15-O) Water
Description: Injection of radiolabelled water. H2\[15-O\] is a radioactive material. Each patient will have eight H2\[15-O\] blood flow scans. For each O-15 water scan 20 mCi of H2\[15O\] will be injected as an intravenous bolus.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oxygen (15-O) Water
Description: Injection of radiolabelled water. H2\[15-O\] is a radioactive material. Each patient will have eight H2\[15-O\] blood flow scans. For each O-15 water scan 20 mCi of H2\[15O\] will be injected as an intravenous bolus.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham stimulation of vagus during opioid cue exposure. Each subject in the SHAM group will undergo the action of administering the intervention, but the device will be programmed such that the stimulation will not activate the vagus nerve.
Study: NCT04633421

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PRECISe protocol EN 8g protein/100kcal
Description: Enteral feed containing 8g protein/100kcal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PRECISe protocol EN 5g protein/100kcal
Description: Enteral feed containing 5g protein/100kcal
Study: NCT03738852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: Continuous Glucose Monitor (CGM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: standard insulin regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: standard insulin regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: standard insulin regimen
Study: NCT03926481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluate Healthy Lifestyle Program on cognitive outcomes
Description: The healthy lifestyle program will be delivered once a week for 17 weeks as part as regular clinical care. It will include an group classes taught by health coaches and dieticians. These classes will focus on diet, exercise, and behavior modification. We plan 2 cohorts of 15 subjects (n=30). In-person research assistant-led assessments will occur at baseline and 17 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluate Healthy Lifestyle Program on cognitive outcomes
Description: The healthy lifestyle program will be delivered once a week for 17 weeks as part as regular clinical care. It will include an group classes taught by health coaches and dieticians. These classes will focus on diet, exercise, and behavior modification. We plan 2 cohorts of 15 subjects (n=30). In-person research assistant-led assessments will occur at baseline and 17 weeks.
Study: NCT03255512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: 2.5 mg/tablet; 5 mg/tablet or 10 mg/tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isosorbide mononitrate (ISMN)
Description: 30 mg/tablet or 60 mg/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN)
Description: 30 mg/tablet or 60 mg/tablet
Study: NCT01693627

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pinnacle/Corail with collar
Description: Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marathon/Corail with collar
Description: Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pinnacle/Corail without collar
Description: Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marathon/Corail without collar
Description: Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
Study: NCT01746264

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D 3 at 100,000 IU once a month for 3 months
Study: NCT01509742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
Study: NCT03734211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: 420 mg evolocumab will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
Study: NCT03344926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTsmart
Description: Participant receive ACT treatment via a smart phone application, including psychologist support via a message function within the application.~Treatment content is divided into four modules:~1. education about pain behaviors, exposure and acceptance and commitment therapy~2. education about pain physiology~3. exercises on changing behaviors, acceptance, mindfulness, defusion and exposure~4. value based exposure in the participant's daily life
Study: NCT03939325

Intervention type: RADIATION
Intervention: ESWL
Description: The impact of different frequencies on pattern of disintegration of renal stones

Intervention type: RADIATION
Intervention: ESWL
Description: The impact of different frequencies on pattern of disintegration of renal stones

Intervention type: RADIATION
Intervention: ESWL
Description: The impact of different frequencies on pattern of disintegration of renal stones
Study: NCT02299817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Prolia is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.~Prolia is also used to treat bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Prolia reduces the risk of fractures in the spine.~Recently denosumab was found to be effective in preventing osteoporosis related fractures in post-menopausal women by blocking RANKL and thereby inhibiting the development and activity of osteoclast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03334721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 5 day trial of gabapentin with titration to 1,200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 5 day trial of gabapentin with titration to 1,200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: 5 day trial of matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: 5 day trial of matched placebo
Study: NCT03858166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: 6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-rhG-CSF
Description: 6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.
Study: NCT01859806

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticogastrostomy group
Description: Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isolated Roux PJ group
Description: Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
Study: NCT03203135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional prevention programme
Description: The nutritional prevention programme will offer a wide range of food and physical activity activities adapted to the life of the company (example: culinary demonstration, physical activity, provision of fruit baskets, etc.) .
Study: NCT02806258

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Description: To date, there is no report on external beam APBI associated with CT in the neoadjuvant setting.In the NeoAPBI 01 trial, the objective is to demonstrate the efficacy of combined APBI and CT administered sequentially in patients with intermediate ad high risk BC. The hypothesis is that combined PST-sequential APBI may increase the rate of pCR, breast conservation and survival without additional toxicity, as seen with WBI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: minimum of six cycles of PST using anthracycline and/or taxane based regimens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: minimum of six cycles of PST using anthracycline and/or taxane based regimens
Study: NCT04216758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur
Description: Patients secondly receive tegafur Body surface area \< 1.25 m\^2, 60 mg/d;Body surface area ≥ 1.25 m\^2 to \< 1.5 m\^2, 80 mg/d;Body surface area ≥ 1.5 m\^2, 100 mg/d (po) on days 1-21 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study: NCT02238483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7624 1.0 mg
Description: Inhaled AZD7624 solution, 11 mg/mL
Study: NCT00982449

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIAU-PET-CT-2
Description: 1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIAU-PET-CT-4
Description: 1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT
Study: NCT01880125

Intervention type: DRUG
Group type: OTHER
Intervention: Tramadol HCI/Acetaminophen
Description: Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
Study: NCT02238483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo solution
Study: NCT03476811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Marcaine at 2ml/hr and pain medications
Description: Subcutaneous pain control with OnQ Subcutaneous Drug pump

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placement of OnQ Drug pump
Description: Subcutaneous placement of OnQ drug pump with normal saline infusion
Study: NCT02574455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: 10 mg/kg administered as a slow intravenous (IV) infusion either by gravity or with an infusion pump. Infusion rate for the first 15 minutes will start with 50 mg/hour or less with a subsequent infusion of 100 to 200 mg/hour up to a maximum recommended rate (advanced every 15 to 30 minutes) of 500 mg/hour with a subsequent infusion of 1000 mg/hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Administered IV over 2 to 5 minutes at a dose 1.4 mg/m\^2 at North American sites and 1.23 mg/m\^2 at European sites on Days 1 and 8 of a 21-day cycle for up to 15.3 months. Lower doses will be administered on the same schedule to participants with moderate hepatic impairment (ie, Child-Pugh B; 0.7 mg/m\^2 and 0.67 mg/m\^2 for North American and European sites, respectively).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 800 to 1200 mg/m\^2 will be administered IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle for up to 8.1 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: 25 mg/m\^2 will be administered as a weekly IV injection over 6-10 minutes for up to 11.5 months. Vinorelbine will not be allowed as TPC for any participant with Grade 2 neuropathy.
Study: NCT03199209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Receive information about healthy lifestyles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Receive information about healthy homes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Visit
Description: Attend study visit with research staff

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Visit
Description: Attend study visit with research staff

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive information about healthy lifestyles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive texts about healthy homes
Study: NCT01655888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is administered as endovenous infusion
Study: NCT04718688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO-OP rehabilitation
Description: The intervention was included within the child's conventional rehabilitation program.~In the CO-OP original protocol, the child sets 3 goals. Here, we concentrated on two rather than three goals, as addressing three occupations per session seemed too ambitious given the children's cognitive profile (the third goal served as control goal).~We chose to increase the number of sessions to 14 (two sessions per week for seven weeks, vs ten in the original protocol).~The global strategy was taught to the child at the first session. The following sessions consisted of an iterative process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the children were experiencing when performing the self-selected tasks. In addition, homework was assigned to encourage the application and practice. Parents were invited to attend the sessions if it was possible for them.
Study: NCT01186198

Intervention type: DEVICE
Intervention: MINI TREK RX 1.20 mm Coronary Dilatation Catheter
Description: Enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
Study: NCT02206269

Intervention type: DEVICE
Intervention: Alair System
Description: The Alair system is used for doing bronchial thermoplasty.
Study: NCT04982536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VMCore Biopsy System
Description: Prostate Examine
Study: NCT00645918

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clopidogrel
Description: oral, 75 mg daily for 6 months starting on day of randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clopidogrel
Description: oral, 75 mg daily for 6 months starting on day of randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
Study: NCT04982536

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Biopsy Needle
Description: Prostate Examine
Study: NCT01514344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intralesional rituximab
Description: 10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: supplemental autologous serum
Description: patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum